Match!
Sudhakar Sahoo
University of Manchester
12Publications
3H-index
44Citations
Publications 12
Newest
#1Sumitra Mohan (University of Manchester)H-Index: 1
#2Mahmood Ayub (University of Manchester)H-Index: 7
Last.Gerard Brady (University of Manchester)H-Index: 29
view all 17 authors...
Serial biopsy of pancreatic ductal adenocarcinoma (PDAC), to chart tumour evolution presents a significant challenge. We examined the utility of circulating free DNA (cfDNA) as a minimally invasive approach across a cohort of 55 treatment-naive patients with PDAC; 31 with metastatic and 24 with locally advanced disease. Somatic mutations in cfDNA were detected using next generation sequencing in 15/24 (62.5%) and 27/31 (87%) of patients with locally advanced and metastatic disease, respectively....
Source
#1Sumitra Mohan (University of Manchester)H-Index: 1
#2Victoria Foy (University of Manchester)H-Index: 3
Last.Gerard Brady (University of Manchester)H-Index: 29
view all 19 authors...
Abstract Introduction Small cell lung cancer (SCLC) accounts for ∼250,000 deaths worldwide each year. Acquisition of adequate tumour biopsies is challenging and liquid biopsies present an alternative option for patient stratification and response monitoring. Methods We applied whole genome next-generation sequencing (NGS) to circulating-free DNA (cfDNA) from 39 patients with limited-stage (LS-SCLC) and 30 of patients with extensive-stage (ES-SCLC) to establish genome wide copy number aberrations...
1 CitationsSource
#2Peter MageeH-Index: 4
Last.Michela GarofaloH-Index: 29
view all 8 authors...
Introduction: EML4-ALK-driven lung cancer represents about 5% of lung adenocarcinomas. Despite the constant expansion of the armamentarium to inhibit ALK, patients typically develop acquired resistance to ALK inhibitors. In the case of resistance mediated by ALK mutations, sequencing of ALK inhibitors is recommended, but in ALK wild-type patients, a better understanding of acquired resistance, as well as new therapeutic strategies are needed. Here, we aimed to characterize the transcriptional ne...
Source
#1Pedro Torres-Ayuso (University of Manchester)H-Index: 7
#2Sudhakar Sahoo (University of Manchester)H-Index: 3
Last.John Brognard (University of Manchester)H-Index: 20
view all 16 authors...
Precision medicine aims to tailor cancer therapies to target specific tumor-promoting aberrations. For tumors that lack actionable drivers, which occurs frequently in the clinic, extensive molecular characterization and pre-clinical drug efficacy studies will be required. A cell line maintained at low passage and a patient- derived xenograft model (PDX) were generated using a fresh biopsy from a patient with a poorly-differentiated neuroendocrine tumor of unknown primary origin. Next-generation ...
2 CitationsSource
#1Sumitra MohanH-Index: 9
#2Victoria FoyH-Index: 3
Last.Gerard BradyH-Index: 29
view all 17 authors...
Introduction: Tumor genomes can be reconstructed from the molecular information obtained from circulating cell-free DNA (cfDNA) and circulating tumor cells (CTCs) obtained from the peripheral blood of patients with cancer. The analysis of cfDNA and CTCs is a minimally invasive approach and represents a powerful research tool, with potential as a companion diagnostic for both patient stratification and monitoring. Here, we use cfDNA next-generation sequencing (NGS) analysis to assess and compare ...
1 CitationsSource
#1Alba Maiques-Diaz (University of Manchester)H-Index: 4
#2Gary J. Spencer (University of Manchester)H-Index: 8
Last.Tim C.P. Somervaille (University of Manchester)H-Index: 22
view all 17 authors...
Summary Pharmacologic inhibition of LSD1 promotes blast cell differentiation in acute myeloid leukemia (AML) with MLL translocations. The assumption has been that differentiation is induced through blockade of LSD1's histone demethylase activity. However, we observed that rapid, extensive, drug-induced changes in transcription occurred without genome-wide accumulation of the histone modifications targeted for demethylation by LSD1 at sites of LSD1 binding and that a demethylase-defective mutant ...
22 CitationsSource
#1Lei Shi (University of Manchester)H-Index: 3
#2Justin Middleton (OSU: Ohio State University)H-Index: 8
Last.Michela Garofalo (University of Manchester)H-Index: 29
view all 13 authors...
Oncogenic KRAS induces tumor onset and development by modulating gene expression via different molecular mechanisms. MicroRNAs (miRNAs) are small non-coding RNAs that have been established as main players in tumorigenesis. By overexpressing wild type or mutant KRAS (KRASG12D) and using inducible human and mouse cell lines, we analyzed KRAS-regulated microRNAs in non-small-cell lung cancer (NSCLC). We show that miR-30c and miR-21 are significantly upregulated by both KRAS isoforms and induce drug...
4 CitationsSource
#2Sudhakar SahooH-Index: 3
Last.John BrognardH-Index: 20
view all 11 authors...
Precision medicine aims to tailor cancer therapies to target specific tumorpromoting aberrations. For tumors that lack actionable drivers, extensive molecular characterization and pre-clinical drug efficacy studies will be required to match patients with the appropriate targeted therapy. A cell line maintained at low passage and a patient- derived xenograft model (PDX) were generated using a fresh biopsy from a patient with a poorly-differentiated neuroendocrine tumor of unknown primary origin. ...
Source
#1Pedro Torres-AyusoH-Index: 7
#2Sudhakar SahooH-Index: 3
Last.John BrognardH-Index: 20
view all 11 authors...
Background: Precision medicine aims to tailor cancer therapies to target specific tumor-promoting aberrations. For tumors that lack actionable drivers, extensive molecular characterization and preclinical drug efficacy studies will be required to match a patient with the appropriate targeted therapy. Patients and Methods: Next-generation sequencing, high-throughput signaling network analysis, and drug efficacy trials were used in a tumor-derived cell line and a patient-derived xenograft (PDX) mo...
Source
#1Srivatsava Naidu (University of Manchester)H-Index: 10
#2Lei Shi (University of Manchester)H-Index: 3
Last.Michela Garofalo (University of Manchester)H-Index: 29
view all 13 authors...
In NSCLC alterations in PDGF receptors are markers of worst prognosis and efficient targeting of these receptors is yet to be achieved. In this study, we explored PDGFR-regulated microRNAs demonstrating that miR-23b cluster and miR-125a-5p are downregulated by increased expression of PDGFR-α or PDGFR-β in NSCLC cells. Mechanistically, the expression of these microRNAs is positively regulated by p53 and negatively modulated by NF-kB p65. Forced expression of miR-23b cluster or miR-125a-5p enhance...
15 CitationsSource
12